CY1112816T1 - Σταθερη φαρμακευτικη συνθεση για τη βελτιστοποιημενη χορhγηση αναστολεα συνδεσης του ηiv - Google Patents

Σταθερη φαρμακευτικη συνθεση για τη βελτιστοποιημενη χορhγηση αναστολεα συνδεσης του ηiv

Info

Publication number
CY1112816T1
CY1112816T1 CY20121100500T CY121100500T CY1112816T1 CY 1112816 T1 CY1112816 T1 CY 1112816T1 CY 20121100500 T CY20121100500 T CY 20121100500T CY 121100500 T CY121100500 T CY 121100500T CY 1112816 T1 CY1112816 T1 CY 1112816T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
hiv
connector
stable pharmaceutical
optimized administration
Prior art date
Application number
CY20121100500T
Other languages
Greek (el)
English (en)
Inventor
Jonathan R Brown
Helen Toale
Andrew B Dennis
Peter Timmins
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1112816T1 publication Critical patent/CY1112816T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/062Organo-phosphoranes without P-C bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20121100500T 2008-09-04 2012-06-01 Σταθερη φαρμακευτικη συνθεση για τη βελτιστοποιημενη χορhγηση αναστολεα συνδεσης του ηiv CY1112816T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9413108P 2008-09-04 2008-09-04
EP09792207A EP2323633B1 (en) 2008-09-04 2009-09-03 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor

Publications (1)

Publication Number Publication Date
CY1112816T1 true CY1112816T1 (el) 2016-02-10

Family

ID=41726353

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100500T CY1112816T1 (el) 2008-09-04 2012-06-01 Σταθερη φαρμακευτικη συνθεση για τη βελτιστοποιημενη χορhγηση αναστολεα συνδεσης του ηiv

Country Status (16)

Country Link
US (2) US20100056540A1 (https=)
EP (1) EP2323633B1 (https=)
JP (1) JP5638527B2 (https=)
CN (1) CN102143739B (https=)
AT (1) ATE550016T1 (https=)
CA (1) CA2735008C (https=)
CY (1) CY1112816T1 (https=)
DK (1) DK2323633T3 (https=)
ES (1) ES2383149T3 (https=)
HR (1) HRP20120441T1 (https=)
NL (1) NL301118I2 (https=)
PL (1) PL2323633T3 (https=)
PT (1) PT2323633E (https=)
SI (1) SI2323633T1 (https=)
SM (1) SMT201200029B (https=)
WO (1) WO2010028108A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248139B2 (en) 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
JP2686215B2 (ja) * 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents

Also Published As

Publication number Publication date
SMT201200029B (it) 2012-09-07
NL301118I2 (nl) 2022-02-22
US20100056540A1 (en) 2010-03-04
PT2323633E (pt) 2012-05-29
CN102143739A (zh) 2011-08-03
HRP20120441T1 (hr) 2012-06-30
NL301118I1 (https=) 2021-07-23
ATE550016T1 (de) 2012-04-15
CN102143739B (zh) 2014-12-17
EP2323633B1 (en) 2012-03-21
JP2012502042A (ja) 2012-01-26
ES2383149T3 (es) 2012-06-18
CA2735008A1 (en) 2010-03-11
US20150158891A1 (en) 2015-06-11
WO2010028108A3 (en) 2010-09-02
DK2323633T3 (da) 2012-07-09
EP2323633A2 (en) 2011-05-25
WO2010028108A2 (en) 2010-03-11
CA2735008C (en) 2016-11-29
JP5638527B2 (ja) 2014-12-10
PL2323633T3 (pl) 2012-08-31
SI2323633T1 (sl) 2012-07-31

Similar Documents

Publication Publication Date Title
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
WO2009032034A3 (en) Stabilized picoplatin dosage form
CL2010001279A1 (es) Forma de dosificacion que comprende 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato, un vehiculo lipidico, un espesante y un agente de deslizamiento/solubilizante, de grupos definidos.
MX2011006578A (es) Formulaciones farmaceuticas de liberacion prolongada.
MY174001A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
UA106378C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
WO2008000731A3 (en) Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20090346L (no) Pyrazolderivater som inhibitorer av cytokrom P450
GB2459393B (en) Novel capsule formulation for the proton pump inhibitor omeprazole
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
WO2008006795A3 (en) Indole compounds
MX2008013040A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1.
WO2010130773A3 (en) Benzoxazolone derivatives as aldosterone symthase inhibitors
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe
NL301118I2 (nl) Fostemsavir
UA94251C2 (ru) Индолпроизводная соль лимонной кислоты и ее фармацевтическое применение
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa
WO2013188465A3 (en) Treating drug addiction and preventing drug relapse
CY1110717T1 (el) Ενα πρωτοτυπο συστημα χορηγησης φαρμακου για τους αναστολεις αντλιας πρωτονιων και τις διαδικασιες τους
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
WO2008015530A3 (en) Stable solid oral formulation of pantoprazole